Charles River Laboratories International Inc. (NYSE:CRL) – Analysts at SunTrust Banks reduced their Q4 2016 earnings estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Tuesday. SunTrust Banks analyst S. Draper now forecasts that the brokerage will post earnings of $1.11 per share for the quarter, down from their previous estimate of $1.15. SunTrust Banks also issued estimates for Charles River Laboratories International’s Q2 2017 earnings at $1.30 EPS, FY2017 earnings at $5.05 EPS and FY2018 earnings at $5.58 EPS.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 2nd. The company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.05. The firm had revenue of $425.70 million for the quarter, compared to analysts’ expectations of $291.20 million. Charles River Laboratories International had a return on equity of 25.11% and a net margin of 9.05%. The company’s quarterly revenue was up 21.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.03 earnings per share.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

CRL has been the topic of a number of other reports. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research note on Wednesday, October 5th. Credit Suisse Group AG reaffirmed a “neutral” rating on shares of Charles River Laboratories International in a research note on Friday, September 30th. Evercore ISI reaffirmed a “hold” rating and issued a $91.50 price target (up from $83.50) on shares of Charles River Laboratories International in a research note on Thursday, August 4th. Citigroup Inc. raised their price target on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Thursday, August 4th. Finally, Jefferies Group raised their price target on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $84.46.

Charles River Laboratories International (NYSE:CRL) opened at 75.35 on Wednesday. Charles River Laboratories International has a 1-year low of $65.70 and a 1-year high of $89.18. The company has a market cap of $3.57 billion, a PE ratio of 25.46 and a beta of 1.18. The stock’s 50 day moving average price is $79.45 and its 200-day moving average price is $82.48.

A number of hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System increased its stake in Charles River Laboratories International by 7.1% in the first quarter. Arizona State Retirement System now owns 25,594 shares of the company’s stock valued at $1,944,000 after buying an additional 1,700 shares during the period. Panagora Asset Management Inc. increased its stake in Charles River Laboratories International by 7.0% in the first quarter. Panagora Asset Management Inc. now owns 399,468 shares of the company’s stock valued at $30,336,000 after buying an additional 26,165 shares during the period. Barclays PLC increased its stake in Charles River Laboratories International by 18.2% in the first quarter. Barclays PLC now owns 18,449 shares of the company’s stock valued at $1,384,000 after buying an additional 2,847 shares during the period. Samlyn Capital LLC bought a new stake in Charles River Laboratories International during the first quarter valued at $20,299,000. Finally, Aristotle Capital Boston LLC increased its stake in Charles River Laboratories International by 7.0% in the first quarter. Aristotle Capital Boston LLC now owns 48,167 shares of the company’s stock valued at $3,658,000 after buying an additional 3,155 shares during the period. Hedge funds and other institutional investors own 97.12% of the company’s stock.

In related news, insider Davide Molho sold 7,877 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $84.10, for a total value of $662,455.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.